Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection

Bone Marrow Transplantation

Volumn 41, Issue 1, 2008, Pages 39-43

  Byrne, B J ^a   Horwitz, M ^a   Long, G D ^a   Gasparetto, C ^a   Sullivan, K M ^a   Chute, J ^a   Chao, N J ^a   Rizzieri, D A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BONE MARROW DEPRESSION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DONOR SELECTION; GASTROINTESTINAL DISEASE; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HUMAN; KIDNEY CANCER; KIDNEY FAILURE; LUNG HEMORRHAGE; MORTALITY; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REMISSION; RETRANSPLANTATION; SIDE EFFECT; SKIN DISEASE; STREPTOCOCCUS INFECTION; SURVIVAL TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION; VOMITING; WHOLE BODY RADIATION;

ADULT; AGED; CARCINOMA, RENAL CELL; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY NEOPLASMS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 38349049150     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705882     Document Type: Article

References (19)

1. McSweeney P, Niederwieser D, Shizuru J, Sandmaier B, Molina A, Maloney D et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
2. Barrett AJ, Savan BN. Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661-1672.
3. Narimatsu H, Kami M, Miyakoshi S, Murashige N, Yuji K, Hamaki T et al Graft failuire following reduced-intensity cord blood transplantation for adult patients. Br. J Haematol 2006: 132 36-41.
4. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
5. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690-697.
6. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Gong JZ, Lagoo A et al Outcome and immune reconstitution following T cell depleted nonmyeloablative allogeneic transplantation using matched donors. Blood 2005; 106 (suppl): 2036, Abstract.
7. http://ctep.cancer.gov/forms/ctcaev3to2.pdf.
8. Laughlin M, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815-1822.
9. Fielding A, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007; 109 944-950.
10. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
11. Quinones RR. Hematopoietic engraftment and graft failure after bone marrow transplantation. Am J Pediatr Hematol Oncol 1993; 15: 3-17.
12. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow, transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197-204.
13. Bunjes D, Heit W, Arnold R, Schmeiser T, Wiesneth M, Carbonell F et al. Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts. Transplantation 1987; 43: 501-505.
14. Walshe J, Bishop MR. Factors affecting engraftment of allogeneic hematopoietic stem cells after reduced-intensity conditioning. Cytotherapy 2004; 6: 589-602.
15. Storb R, Thomas ED, Buckner CD, Appelbaum FR, Clift RA, Deeg HJ et al Marrow transplantation for aplastic anemia. Semin Hematol 1984; 21: 27-35.
16. Bishop MR, Steinberg SM, Gress RE, Hardy NM, Marchigiani D, Kasten-Sportes C et al. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol 2004; 126: 837-843.
17. Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following non-myeloablative conditioning. Leukemia 2006; 20: 1690-1700.
18. Hows JM. Mechanisms of graft failure after human marrow transplantation: a review. Immunol Lett 1991; 29: 77-80.
19. Ruiz-Arguelles GJ, Gomez-Almaguer D, Tarin-Arzaga LD, Morales-Toquero A, Cantu-Rodriguez OG, Manzano C. Second allogeneic peripheral blood stem cell transplants with reduced-intensity conditioning. Rev Invest Clin 2006; 58: 34-38.